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This study examined competitive intelligence and product development 
and innovation in pharmaceutical firms in Lagos State, Nigeria. Three 
hypotheses were formulated to determine whether or not a relationship 
exist between competitive intelligence and product development and 
innovation in pharmaceutical firms in Lagos State, Nigeria. The study 
adopted a survey research design to obtain data, using a structured 
questionnaire which was analyzed using Pearson’s product moment 
coefficient of correlation. The result indicated that there exists a 
significant relationship between competitive intelligence and product 
development and innovation in pharmaceutical firms in Lagos State, 
Nigeria. Based on the finding it was concluded that the process of product 
development and innovation cannot be successful except there is 
information about customer’s needs, wants and expectations of which the 
innovation products or services intends to serve. The study recommended 
among others that pharmaceutical firms should leverage on information 
gathering and sharing to determine the nature of the new product and 
service so that the new product offerings will be more valued and 
satisfying than the existing ones that are offered by the competitors.   
 
Keywords:  Competitive Intelligence, Information gathering and 
sharing, Product Development and innovations, New products, New 




Competitive intelligence has remained a significant mediating variable for success 
in the business world today as its part of the strategies employed by organization for 
survival and expansion as organizations are experiencing increasing competition 
occasioned by globalization, glocalization, advanced technology, social economic 
variables and marketing dynamics. The marketing environment today has become 
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survival of the fittest and many struggled to survive to keep pace with the changing and 
dynamic environmental conditions. The need to know competitors and monitor their 
activities in the market place becomes imperative. To come to terms with this reality 
pharmaceutical firms are now focusing their strategies on product development and 
innovation. For a product to secure good position, market acceptance and a fair share of 
the market it must first find out the customer’s needs, wants and expectations and develop 
product to meet their divergent requirements.  
To achieve these objectives pertinent and actionable information must be available 
to empower organizations in information gathering and sharing. Competitive intelligence 
equips organization with the necessary information and knowledge needed for product 
development and innovation in the current information age in which knowledge is power 
(Haag and Cummings 2009). It is most pardonable to be beaten by competition but 
abhorrent to be taken by surprise, therefore it is most important to take proactive actions 
to identify the early warning signals as they occur in the market. For organization to 
survive and remain in the competitive aggressive and turbulent environment, the need for 
better and understanding and knowledge of the competitive forces that reshape the 
behavior of the environment cannot be over emphasized.  
Karim (2011) agrees that knowledge is the main sources of product development 
and innovation, similarly, according to Ishikawa and Nakagawa (2013) those 
organizations that can understand their environment, their competitors and establish 
competitive management strategies will win in this rapidly globalized information 
society.  
Therefore, having access to information and knowledge of the environment, and 
application of the intelligent information are essential element for organizational survival. 
According to Anica-Popa and Cucui (2009) competitive intelligence is the acquisition of 
and use of knowledge and information about competitors, customers, suppliers and 
support decision making process that will enhance competitiveness of the organization. 
The process of product development and innovation cannot be successful except there is 
information about customer’s needs and requirements of which the innovated products or 
services intends to serve. Such information gathering and sharing no doubt will determine 
the nature of the new product and service so that the new product offerings will be more 
valued and satisfying than the existing ones that are provided by the competitors.   
The strict regulations by government in the pharmaceutical industry today has 
become more critical for competitive intelligence as competitive intensity in the industry 
has increased due to technological complexities, products availability and variety and 
consumer sophistication. Therefore, for a pharmaceutical firm to improve on their 
performance and stand the test of time they must leverage on useful information gathered 
in their environment to engage not only in new product development and innovation but 
also constantly making relevant modifications to their existing product offerings to suit 
the market expectations and cope with the ever changing environment. This study shall 
examine the influence of competitive intelligence on product development and innovation 
in pharmaceutical firms in Lagos State, Nigeria.   
 
1.1 Statement of the Problem 
Industries these days are struggling for survival as a result of the stern competition 
occasioned by globalization, glocalization, advanced technology, socio-economic 
variables and other marketing dynamics. Instead of competitive intelligence to aid 
productivity and enhance performance as an intervening variable, reverse is the case, thus, 
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creating a negative relationship among competing firms in the same industry, therefore 
managers of firms are compelled to adopt strategies that will enable them break away 
from the pack at all cost, hence indulge in clandestine industrial espionage. 
Competitive intelligence ought to be a significant intervening variable for 
enhancing productivity, by its information gathering and sharing, analysis and 
interpretations and speculative consideration of future development patterns, risk and 
opportunities through the existence of human judgment.   
Competitive intelligence is viewed as a process by the practitioners as it involves 
a set of legal and ethical methods for collecting, development, analyzing and 
disseminating actionable intelligence regarding competitors, suppliers, customers, the 
organization itself and business environment whose pressure has an underpinning with 
the improvement and performance of the organization to gain and sustain competitive 
advantage. For an organization to compete effectively in an environment that is in the 
state of flux, dynamic and changing nature and character, there is the need for inward and 
forward looking in terms of advance competitive opportunities, threats and industrial 
espionage and spy stuff as in the case of Nigeria Pharmaceutical industries.  
Unhealthy competition has characterized Nigeria pharmaceutical industries as a 
result of industrial espionage, spy stuff, chronic hunger for target achievement, 
competitors profiling and information analysis either in the form of counterfeiting, 
swapping, re-coding of product eg. panadol, paracetamol, bonadol, etc also Aspirin, 
lisinoprin, vasoprin etc in the name of competitive intelligence.  
These unethical and unhealthy competitive practices have been under serious 
attacks and condemnation occasioned by the fatalities accompanying the practice such 
that if not promptly checked could lead to loss of public legitimacy in the pharmaceutical 
industries and crisis in the health sectors as a whole.   
Interestingly, a good number of measures have been put in place to reverse these 
negative trends to salvage the imminent crisis in the health sector. It is against this 
background that this research was conceived to proactively proffer effective strategies for 
solution to the looming danger in the competitive nature of competitive intelligence 
practice in the pharmaceutical sector in Lagos State. 
 
1.2 Objectives of the Study 
The broad objective of this study was to access and examine the nature of the 
relationship between competitive intelligence and product development and innovation 
in pharmaceutical firms while the specific objectives of the study are stated inter-alia: 
1. To determine if competitive intelligence practice influences product development and 
innovations in Pharmaceutical firms. 
2. To ascertain if competitive intelligence application has derived benefits. 
3. To establish if pharmaceutical firms faces any challenge in applying competitive 
intelligence. 
 
1.3 Research Questions 
The under-listed research questions were raised in an attempt to achieve the 
objectives stated above. 
1. How does competitive intelligence influence product development and innovation in 
Pharmaceutical firms? 
2. What are the benefits derivable from competitive intelligence? 
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3. In applying competitive intelligence, what are the challenges faced by pharmaceutical 
firms. 
 
2. THEORETICAL FRAMEWORK AND HYPOTHESES 
2.1 Conceptual Review 
 Competitive intelligence is yet another new concept in the field of management. 
It was the creation of porter five forces as a concept and new generated idea (Pellissier 
and Nenzhelele 2013). This concept made efforts to unravel some striking definitions and 
discussions as put forward by scholars and authors from different schools of thought. The 
society of competitive intelligence professionals, SCIP (2013) defined competitive 
intelligence as a systematic and ethical process for gathering, analyzing and managing 
external information that can affect the company’s plans, decisions and operations. 
According to Colakoglu (2011) competitive intelligence means a systematic process 
initiated by organizations in order to gather and analyze information about competitors 
and the general socio-political and economic environment of the firm. The idea of this 
concept is to formulate a process of monitoring the competitive environment, with the 
sole aim of providing actionable intelligence that ensures competitive advantage to the 
organization (Kahaner 1997). The author also identified four objectives in relation to 
competitive intelligence, the first is to discover customers and competitors that are 
potentially new that can lend support to the environment of new business, secondly, the 
identification and analyses of new technologies product and process capable of 
influencing behavior and activities of the organization. Thirdly, identification and 
analyses of political and legal standards which acts as a regulation to influence behavior 
and activities of the organization and finally, identification and analysis of condition of 
competitors, suppliers among others that can translate into success or failure. In the 
opinion of McGonagle and Vella (2002) competitive intelligence was described as a 
formalized but developing process that is used by managers to evaluate the evolution of 
their industry and the capabilities and behavior of their competitors and those who might 
be their competitors in future. To support this assertion Teo and Choo (2001) assumed 
that competitive intelligence is the analytical process that transforms scattered 
information about competitors and customers into relevant, accurate and usable strategic 
knowledge on market evolution, business opportunities and threats. Karim (2011) stated 
that competitive intelligence is a systematic process that allows for identifying 
competitors plans and intentions to gain some advantages. The systematic process 
involves collecting, processing, analyzing, and distributing to top management and other 
decision makers any information about an organization’s external environment. 
According to Blenkhorn and Fleisher (2005) competitive intelligence is a continuously 
evolving process that involves discovering, analyzing and using intelligence regarding 
competitors and general business environment from publicly available, non-proprietary 
information sources and converting it into knowledge on a continuing basis. Priporas et 
al. (2005) postulated that competitive intelligence can be considered as both a product 
and a process. 
The product is data on the firm’s competitors that is used as the foundation for 
action. The process is the methodical acquisition, analysis and evaluation of data for 
competitive advantage over known and potential competitors. Strategic decisions are 
made by executives through the help of these data that enable them to understand their 
competitors. Wheelen (2010) as cited in Charity and Joseph (2013) defined competitive 
intelligence as a formal program of gathering information on company’s competitors. It 
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is one of the fastest growing field within strategic management. Similarly, Rabaey et al. 
(2006) sees competitive intelligence as a structured judicious method and informing 
strategy and an innovation engine that draws better business outcome. To Haataja 
(2011)competitive intelligence is a strategic tool that helps enterprise to be aware of their 
competitors’ behavior and plans. It produces actionable intelligence that in turn helps 
enterprises in decision making and good decision leads to higher achievements, hence 
competitive intelligence is being regarded as tool that helps enterprises to improve their 
performance (LI et al. 2011).          
 
2.2 Theoretical Review   
A good number of theories have been developed by scholars and authors from 
different schools of thought in order to buttress the authenticity of the subject matter. In 
this study the “open system theory” is adopted.   
The theory was propounded by Ludwig von Bertanlanffy in 1956. Open system 
theory holds the view that organizations are strongly influenced by their internal and 
external environmental variables. The environment is made up of other actors that exert 
considerable and significant pressure such as political, socio-cultural, economic and 
technological, etc. and other internal environmental forces that influence the organization 
in different magnitudes. As these forces inter play in the environment, they possess 
boundaries that are visibly porous which permits interaction across the boundaries to 
enable new ideas and information infiltrations to bring about cross fertilization of viable 
ideas. In response to the above, organizations can adapt more quickly to the changes in 
the dynamic external environment where they operate. The interactions are a continuous 
flux among the sub-systems in the environment and are significant intervening variables 
for organizational survival and success.   
Thus, any alert and proactive organization that are sensitive to the environment 
can survive, succeed and stand the test of time because of the organization’s dependency 
on these inputs and service outputs.  
Therefore, the aim of this theory is to explain how organization interact with their 
environment through competitive intelligence to gather data, information and knowledge 
about actors in the environment i.e. competitors, customers, suppliers, government etc in 
order to develop and innovate products and services to meet the needs, wants and 
expectations of the customers. Hence, open system theory identifies the concept of 
competitive intelligence as an ethical and legal business practice which seek to gather 
information from external business environment, turn them into actionable intelligence 
and utilizes it for the development and innovation of new products and services to meet 
the divergent needs, wants and expectations of the customers.   
 
Figure 1. Interaction of Organizations with Environment through Competitive Intelligence 




Competitive intelligence  
 
 
Source: Moneme and Nzewi  (2017) Competitive Intelligence and Product Development in selected 
Pharmaceutical Firms in Anambra State, Nigeria 
 
 
 Organizations Competitors/Environment 
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2.3 Empirical Review 
Nte et al. (2020) conducted a study on competitive intelligence and competitive 
advantage in pharmaceutical firms in developing economics: A review of Lagos State, 
Nigeria. The study examines the influence of competitive intelligence on competitive 
advantage of pharmaceutical firms in Lagos State, Nigeria. The study adopted survey 
research design; data were obtained from structured questionnaire and analyzed using the 
one sample t-test statistic. The study discovered among others that competitive 
intelligence is positively associated with the growth of the organization, higher quality 
and performance also that there are significant benefits derivable from competitive 
intelligence practice to guarantee product development and innovation in pharmaceutical 
firms. The study still discovered that there are significant challenges faced by 
pharmaceutical firms when applying competitive intelligence practice. 
The study concluded that the role of competitive intelligence on competitive 
advantage is to provide strategic information that will guide pharmaceutical firms in the 
task of improved marketing innovations to meet the need of customers. The study 
recommended that for a pharmaceutical firm to gain competitive advantage and increase 
their performance they should leverage on useful information gathered in their 
environment to engage not only in product development but also constantly making 
relevant innovation and modifications to their existing marketing strategies. 
Moneme and Nzewi  (2017) carried out a study on competitive intelligence and 
product development in selected pharmaceutical firms in Anambra State, Nigeria. The 
study examines the influence of competitive intelligence on product development in 
selected pharmaceutical firms in Anambra State, Nigeria. Descriptive research design was 
adopted in this study; data were obtained from primary source and analyze using principal 
component analysis and multiple regression analysis. The study found that there is a 
significant relationship between competitive intelligence and product development in 
selected pharmaceutical firms in Anambra State, Nigeria. 
The study concluded that the need to use competitive intelligence became 
imperative in the drive to seek for information in order to know the needs and want of the 
customer before developing products to meet the need and want of the customers. The 
study recommended that firms should place high premium on competitive intelligence if 
they must continue to be relevant to stand the test of time in the ever-changing market 
needs. 
Afolabi et al. (2008) conducted empirical analysis on mobile phones users in 
Nigeria for competitive business intelligence; the main focus of the study was to evaluate 
the interestingness of a set of rules obtained from applying association rule mining 
algorithmic. The study discovered through questionnaire responses on phone brands and 
the number of users that Nokia phone products are the most widely used in Nigeria 
followed by Motorola, as a snapshot of the rules that were generated as a result of the 
application of association rule on the data. 
In conclusion the study stated that the identification of user requirements and 
understanding the user is a major part of contributing to the profit of the organization and 
this can be achieved through competitive intelligence. 
The empirical study by Charity and Joseph (2013) on “managing competitive 
intelligence for strategic advantage” it was found by the study that competitive 
intelligence is necessary because managers need it in their quest for increasing the quality 
of product and services, strategic planning and market knowledge; competitive 
intelligence is a veritable tool used for gathering information, converting the information 
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into intelligence and utilizing the information in business decision making. It is the time 
money and intellectual skill that constitute the cost of competitive intelligence; this study 
showed also that there is a significant positive relationship existing between competitive 
intelligence and strategic advantage. 
In the empirical study by Ain (2013) they examined the role of competitive 
intelligence in multinational companies and the performance of the organization as a 
competitive advantage. The study revealed that competitive intelligence is strongly 
associated with the growth of the organization, higher quality and performance of 
organization to attain a strong position in the market and to meet competencies against its 
competitors.  
The research work by Nwokah and Ondukwu (2009) on competitive intelligence 
and marketing effectiveness in corporate organization in Nigeria. It was recorded by the 
study that there is a strong association between competitive intelligence and marketing 
effectiveness in corporate organizations in Nigeria. Also in the study it was observed that 
competitive intelligence leads to marketing effectiveness in corporate organizations in 
Nigeria. 
The study concluded that knowledge concerning the impact of competitive 
intelligence and marketing effectiveness of corporate organization in Nigeria was 
significantly refined by the study. In recommendation the study reported that management 
should employ adequate measures to consistently motivate its intelligence team so as to 
be able to proactively analyze customer’s need and fashion out strategies to satisfy these 
needs. 
 
2.4 Research Hypotheses 
The following null hypotheses were formulated for the study. 
Ho1:  Competitive intelligence does not significantly influence product development 
and innovation in pharmaceutical firms. 
Ho2:  There are no significant benefits derivable from competitive intelligence practice 
to guarantee product development and innovation in Pharmaceutical firms 
Ho3:  There are no significant challenges faced by Pharmaceutical firms when applying 
competitive intelligence practice. 
 
3. RESEARCH METHOD 
The design of this study was based on survey research; this research design seems 
the best for this study since the intent was to establish whether or not a relationship existed 
between two variables i.e. competitive intelligence and product development and 
innovation.  
 
3.1 Population of the Study  
There are fifty-six (56) Pharmaceutical Companies in Lagos State (Pharma 
approach.com 2017) based on Tabel 1 (Appendix). So, the population of the study 
consists of all the pharmaceutical companies in the state. The list of the companies are 
shown in Table 2 (Appendix). 
 
3.2 Sampling and Sampling Techniques  
The researcher adopted combination of disproportionate stratified and random 
sampling techniques. The disproportionate stratified technique was chosen because of the 
different areas and uneven distribution of the firms. So, in order to make every part of 
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Lagos State be part of the study, the stratified technique was adopted and because the 
companies are not evenly distributed, the researcher was disproportionate in choosing the 
companies. Also, the random technique was adopted in selecting the companies and the 
respondents for the study. 
 
3.3 Sampling Size Determination  
 For the purpose of this study, the sample size is one hundred and ninety-five (195) 
respondents. 
 












1 Ikeja  25 1 BCN plc  15 













5 Mushin  2 1 
Bond Chemical 
industries ltd  
15 
6 Agege  3 
Orfema 
Pharmaceutical 
Industries Limited  
12 15 
7 Okota  1 1 Clatess Limited  15 

























13 Ojota/Ketu  3 1 
Oak-Faith 
Pharmaceutical 
Resource limited  
15 
 Total 56 13 24 195 
Sources: Researchers Compilation 2020 
 
Because of the uneven distribution of the companies in the thirteen areas where 
the companies are located, and locations of the firms, Lagos State is stratified into thirteen 
strata (table 1) and the researcher disproportionately select one (1) company each from 
each of the thirteen strata (area) where the companies are located. This makes it a total of 
thirteen (13) pharmaceutical companies selected for the study. Where the companies are 
more than one the researcher used the random sampling technique to choose one. From 
each company selected for the study, fifteen (15) staff (respondents) were randomly 
selected (five management staff, five senior staff and five junior staff). Multiplying the 
thirteen areas where the companies are located by fifteen staff randomly selected from 
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each company makes it a total of one hundred and ninety-five (195) respondents for the 
study. (See table 2).  
 
3.4 Research Instrument  
The instruments used for collection of data are structural questionnaire designed 
by the researcher. The questionnaire has two parts, Part A and Part B, all the questions in 
Part A provide general information about the respondents while the questions in Part B 
address the research questions, five-point Likert scale format was used. The questionnaire 
contains a total of 40 questions. 
 
3.5 Validity of the Instrument  
In this study when the questionnaire was drafted, it was submitted to five experts 
in the field for their scrutiny, comments and criticisms. This was imperative so as to 
ensure that no important variables were left out. The comments, recommendations and 
useful suggestions were considered in making the final draft.  
 
3.6 Reliability of the Instrument  
 In testing for the reliability of the study, two pharmaceutical firms in Lagos State 
were chosen and thirty staff was selected from the two firms. The Cronbach’s alpha was 
used to test for the reliability of the study. The result of the Cronbach’s alpha coefficient 
of the variables was 83% reliable. This implies that the instrument is reliable. 
 
3.7 Method of Data Collection  
 The method used in the collection of data in this study is questionnaire. The 
primary data used for this study were gathered through questionnaire. A structured 
questionnaire was used in gathering relevant data with options provided for respondents 
on a five-point Likert scale. Response to the items ranges from (5-Strongly Agree (SA), 
(4-Agree (A), (3-Disagree (D), (2- Strongly Disagree (SD) to (1-undecided) (u) 
 
3.8 Method of Data Analysis  
The stated research hypotheses were analyzed using the Pearson’s Product-
Moment Coefficient of Correlation in order to test whether the independent variable 
(competitive intelligence) affect the dependent variable product development and 
innovation. Decision was established based on the results. Decision was established based 
on rejection or acceptance of null hypotheses, if the calculated value exceeds the critical 
value (3.182), reject the null hypothesis, otherwise the• alternative hypothesis will be 
upheld. Or, if the t-value is less than the alpha level (0.05) reject the null hypothesis, 
otherwise accept. The hypotheses were tested at 95% level of confidence.  
 
3.9 Decision Rule  
In testing hypotheses, calculated value of the test statistic was compared with 
critical or table value of the statistic. The critical or table value serves as a benchmark for 
rejecting or not rejecting the null hypotheses. Therefore, the decision rule applied in this 
study is to reject the null hypotheses if the calculated value is greater than the critical 
table at 95% (3.182) confidence level, otherwise reject the null hypotheses. Or reject the 
null hypotheses if the t-value is less than the critical value of 0.05, otherwise accept the 
null hypotheses.  
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4. RESULT AND DISCUSSION 
In the study of competitive intelligence and product development and innovation 
in pharmaceutical companies. In carrying out the study, the researcher used primary 
source of data collection through questionnaire designed by the researcher. A total of one 
hundred and ninety-five (195) questionnaires were distributed and after careful 
monitoring and supervision, one hundred and fifty was retrieved back. This shows 77% 
response rate or 77% interest in the study by the respondents. In analyzing the personal 
data simple percentage was use while in the research questions and hypotheses, the 
Pearson’s Product Moment Coefficient of Correlation is used. 
 
4.1 Analysis of Personal Data 
 
Table 3. Position of Respondents 










Total  150 100 
                  Source: Researchers’ field survey 2020. 
 
The result of table 3 indicates that there are more junior staff in the study with a 
statistic of 47%. A breakdown of the result shows that junior staff has 47%, senior staff 
has 30.2% and management staff has 33%. 
 
Table 4. Sex of Respondents 
Sex  Frequency Percent 
Female  50 33 
Male 100 67 
Total 150 100 
            Source: Researchers’ field survey 2020. 
 
The result of table 4 indicates that there are more male staff in the study with a 
statistic of 67%. A breakdown of the result shows that male staff has 67%, while female 
staff has 33%. 
 
Table 5. Educational Qualification of Respondents 
Educational Qualification  Frequency Percent 
SSCE 40 27 
OND/NCE 60 40 
HND/B.Sc. 30 20 
M.Sc./MBA/PHD 20 13 
Total 150 100 
            Source: Researchers’ field survey 2020. 
 
The result of table 5 indicates that most of the respondents in the study have 
OND/NCE with 40%. A breakdown of the result shows that respondents with SSCE has 27%, 




Omede, et.al., Competitive Intelligence and… .  ISSN : 1412-5366 
  e-ISSN : 2459-9816 
 
JEAM Vol. 19 No. 2, September 2020  102 
 
Table 6. Work Experience of Respondents 
Work experience  Frequency Percent 
Less than 5 28 18 
5-9 years 57 38 
10-14 years 43 29 
Above 14 years 22 15 
Total 150 100 
            Source: Researchers’ field survey 2020. 
 
The result of table 6 indicates that most of the respondents in the study have 
between 5-9 years’ work experience with 38%. A breakdown of the result shows that 
respondents with less than five years’ experience has 18%, 5-9 years has 38%, 10-14 
years has 29% and above l4years working experience has 15%. 
 
Table 7. Respondents View on The Influence of Product Development and 
Innovation in Pharmaceutical Firms by Competitive Intelligence 
S/N Options Frequency Percentage 
1. Strongly Agree 60 40 
2. Agree 40 27 
3. Disagree 25 17 
4. Strongly Disagree 20 13 
5. Undecided 5 3 
 TOTAL 150 100 
        Source: Researcher’s field survey 2020 
 
The table above shows that 60 (28%) of the respondents strongly agreed that 
product development and innovation have a significant influence on pharmaceutical firms 
by competitive intelligence, 40 (27%) agreed, 25 (17%) disagreed, 20 (13%) strongly 
disagreed and 5 (3%) undecided. 
 
Table 8. Respondents Opinion on The Benefits Derivable from Competitive 
Intelligence to Guarantee Product Development and Innovation in 
Pharmaceutical Firms 
S/N Options Frequency Percentage 
1. Strongly Agree 65 44 
2. Agree 35 23 
3. Disagree 25 17 
4. Strongly Disagree 20 13 
5. Undecided 5 3 
 TOTAL 150 100 
        Source: Researcher’s field survey 2020 
 
The above table revealed that 65 (44%) of the respondents strongly agreed that 
there are benefit derivable from competitive intelligence to guarantee product 
development and innovation in pharmaceutical firms, 35 (23%) agreed, 25 (17%) 
disagreed, 20 (13%) strongly disagreed and 5 (3%) undecided. 
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Table 9. Respondents View on The Challenges Faced by Pharmaceutical Firms 
When Applying Competitive Intelligence Practice 
S/N Options Frequency Percentage 
1. Strongly Agree 62 42 
2. Agree 38 25 
3. Disagree 25 17 
4. Strongly Disagree 20 13 
5. Undecided 5 3 
 TOTAL 150 100 
       Source: Researcher’s field survey 2020 
 
The table above shows that 62 (42%) of the respondents strongly agreed that there 
are challenges faced by pharmaceutical firms when applying competitive intelligence 
practice, 38 (25%) agreed, 25 (17%) disagreed, 20 (13%) strongly disagreed and 5 (3%) 
undecided. 
 
4.2 Test of Hypotheses 
To ascertain the validity and reliability of the research outcome, the hypotheses 
are tested using the Pearson’s product-moment coefficient of correlation. 
 
4.2.1 Test of Hypotheses One 
Ho1: Competitive Intelligence does not significantly influence product development 
and innovation in pharmaceutical firms. 
 
Table 10. Respondents View on The Influence of Product Development and 
Innovation in Pharmaceutical Firms by Competitive Intelligence 
S/N Options Frequency Percentage 
1. Strongly Agree 60 40 
2. Agree 40 27 
3. Disagree 25 17 
4. Strongly Disagree 20 13 
5. Undecided 5 3 
 TOTAL 150 100 
         Source: Table 7 
 
Table 11. Contingency Table 
X Y X2 Y2 XY 
5 60 25 3600 300 
4 40 16 1600 160 
3 25 9 625 75 
2 20 4 400 40 
1 5 1 25 5 
15 150 55 6250 580 
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Figure 2. Computation of Hypotheses One 
 
Source: Researcher’s computation, 2020 
 
From the above calculated value 8.5 in Figure 2. (Appendix), when compared with table 
value t = 3.182, at 5% level of significance, the null hypothesis is rejected, while the 
alternative hypothesis is accepted and conclude that there is a significant influence of 
competitive intelligence on product development and innovation. 
 
4.2.2 Test of Hypothesis Two 
Ho2: There are no significant benefits derivable from competitive intelligence practice 
to guarantee product development and innovation in pharmaceutical firms. 
 
Table 12. Respondents Opinion on The Benefits Derivable from Competitive 
Intelligence to Guarantee Product Development and Innovation in 
Pharmaceutical Firms 
S/N Options Frequency Percentage 
1. Strongly Agree 65 44 
2. Agree 35 23 
3. Disagree 25 17 
4. Strongly Disagree 20 13 
5. Undecided 5 3 
 TOTAL 150 100 
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Table 13: Contingency Table 
X Y X2 Y2 XY 
5 65 25 4225 325 
4 35 16 1225 140 
3 25 9 625 75 
2 20 4 400 40 
1 5 1 25 5 
15 150 55 6500 585 
         Source: Researcher’s computation, 2020 
 
Figure 3. Computation of Hypotheses Two 
 
Source: Researcher’s computation, 2020 
 
From the above calculated value 3.819, when compared with table value t = 3.182, 
at 5% level of significance, the null hypothesis is rejected while the alternative hypothesis 
is accepted and conclude that there are benefits derivable from competitive intelligence 
practice to guarantee product development and innovation in pharmaceutical firms. 
 
4.2.3 Test of Hypotheses Three 
Ho1: There are no significant challenges faced by pharmaceutical firms when applying 
competitive intelligence practice. 
Table 14. Respondents View on The Challenges Faced by Pharmaceutical Firms 
When Applying Competitive Intelligence Practice 
S/N Options Frequency Percentage 
1. Strongly Agree 62 42 
2. Agree 38 25 
3. Disagree 25 17 
4. Strongly Disagree 20 13 
5. Undecided 5 3 
 TOTAL 150 100 
       Source: Table 9 
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Table 15. Contingency Table 
X Y X2 Y2 XY 
5 62 25 3844 310 
4 38 16 1444 152 
3 25 9 625 75 
2 20 4 400 40 
1 5 1 25 5 
15 150 55 6338 582 
         Source: Researcher’s computation, 2020 
 
Figure 4. Computation of Hypotheses Three 
 
Source: Researcher’s computation, 2020 
 From the above calculated value 8.4, when compared with table value t = 3.182, 
at 5% level of significance, the null hypothesis is rejected, while the alternative hypothesis 
is accepted and conclude that there are challenges faced by pharmaceutical firms when 
applying competitive intelligence practice. 
 
4.3 Discussion 
This study examined the influence of competitive intelligence on product 
development and innovation in pharmaceutical firms in Lagos state, Nigeria. The finding 
of hypotheses one revealed that there is a significant influence of competitive intelligence 
on product development and innovation in pharmaceutical firm in Lagos State, this is in 
line with the views of Nte et al. (2020) who discovered that competitive intelligence is 
positively associate with the growth of organization, higher quality and performance. In 
the same line of thinking, Moneme and Nzewi (2017) in their study competitive 
intelligence and product development of selected pharmaceutical firms in Anambra State, 
Nigeria that there is a significant relationship existing between competitive intelligence 
and product development.   
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The result of hypotheses two revealed that there is a significant benefits derivable 
from competitive intelligence practice to guarantee product development and innovation 
in pharmaceutical firms, this is in alignment with the views of Charity and Joseph (2013) 
in their study managing competitive intelligence for strategic advantage, it revealed that 
competitive intelligence is necessary because managers need it in their quest for 
increasing the quality of product and services, strategic planning and market knowledge. 
The authors further stated that competitive intelligence is a significant intervening 
variable on competitive advantage in the business world as part of survival and expansion.  
In the same vein, Haag and Cummings (2009) stated that competitive intelligence equips 
organizations with the necessary information and knowledge needed for product 
development and innovation in the current information age in which knowledge is power.  
Hypotheses three revealed that there are significant challenges faced by 
pharmaceutical firms when applying competitive intelligence practice. This agrees with 
the opinion of Nte et al. (2020) who stated that industries are struggling to survive as a 
result of stiff competition created by globalization, glocalization, advance technology, 
socio-economic variables and marketing dynamics. The authors further stressed that 
pharmaceutical firms are enmeshed in a lot of unhealthy medical conundrum as a result 
of industrial espionage, spy stuff, monitoring direct competitors’ behavior and analysis 
of competitor information in form of counterfeiting, swapping, re-coding of products eg. 
panadol, bonadol, paracemol, aspirin, vasoprin, lisinoprin etc in the name of competitive 
intelligence. In alignment with the above, Anica-Popa and Cucui (2009) emphasized the 
need for information gathering and sharing, it was stated that the process of product 
development and innovation cannot be successful except there is information about 
customers’ needs and requirements of which the innovated products or services intends 
to serve. The authors noted that such information gathering and sharing no doubt will 
determine the nature of the new product and service so that the new product offerings will 
be more valued and satisfying than the existing ones that are provided by the competitor. 
Another challenge experienced by the pharmaceutical firms in support of the 
finding of hypotheses three is strict regulation of the pharmaceutical industry by 
government and her agencies. According to Moneme and Nzewi (2017) the strict 
regulation by government in pharmaceutical industry today has become more critical for 
competitive intelligence as competitive intensity in the industry has increased due to 
technological complexities, product availability and variety and consumer sophistication. 
Therefore, for a pharmaceutical firm to improve on their performance and stand the test 
of time they must leverage on useful information gathered from their environment to 
engage not only in new product development and innovations but also to constantly 
making relevant modifications to their existing product offerings to suit the market 
expectations and cope with ever changing environment. 
 
5. CONCLUSION AND SUGGESTION 
5.1 Conclusion  
Competitive intelligence has remained a significant mediating variable on product 
development and innovation in the business world today as part of survival and 
expansion, therefore, the need for competitive intelligence in product development and 
innovation cannot be over emphasized. This study examined the influence of competitive 
intelligence on product development and innovation in pharmaceutical firms in Lagos 
state. The result of the findings revealed among others that competitive intelligence 
significantly influences product development and innovation in pharmaceutical firms.   
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This is because information gathering and sharing by pharmaceutical firms 
determines the nature of the new product and service so that the new product offerings 
will be more valued and satisfying than the existing ones that are provided by the 
competitors.   
The process of product development and innovation cannot be successful except 
there is information about customers’ needs, wants and expectations of which the 
innovated product or service intends to serve. The study concluded that for a 
pharmaceutical firm to improve on their performance and stand the test of time they must 
leverage on useful information gathered in their environment to engage not only in new 
product development and innovation but also constantly making relevant modifications 
to their existing product offerings to suit the market expectations, wants and needs and 
cope with the ever changing and dynamic environment.  
 
5.2 Recommendations  
The following policy recommendations are advanced for the study.   
1. The government should expand the scope of her regulation / measures to ameliorate 
the high level of industrial espionage, spy stuff, counterfeiting, re-coding of product 
etc. in the name of competitive intelligence in order to reverse the looming negative 
trends in the pharmaceutical firms.  
2. The pharmaceutical firms should expand and strengthen their information gathering 
and sharing mechanisms in their environment to engage not only in new product 
development and innovation but also continually making relevant modifications to 
their existing product offerings to suit the market expectation and cope with the ever- 
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APPENDIX 
Table 1. Location of Pharmaceutical Companies in Lagos State 
S/N Area Number of Pharmaceutical Companies 
1. Ikeja 25 
2. Isolo 8 
3. Yaba 2 
4. Ikorodu 1 
5. Mushin 2 
6. Agege 3 
7. Okota 1 
8. Oshodi 3 
9. Ijesha 1 
10. Igando 1 
11. Vitoria Island 3 
12. Badagary 3 
13. Ojota/Ketu 3 
 Total 56 
Sources: Pharmaapproach.com, 2017 and Researchers Compilation 2020. 
